Kringle Pharma (4884) · RiskMitigated
Dependence on the master cell bank license
First written in FY2020. 1 of 2 entries say "Mitigated", first in FY2022. Latest entry: FY2022.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Reliance on External Partners, Including Licensors, Sales Partners and CROsA theme 100 companies write about · 103 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2020: 8 of 42 companies on the "Worse" side.
8 other companies' latest entry also says "Mitigated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 100 companies compared. The sentences above are computed from all 100.Full recordFilings, disclosures and news, newest first
- FY2022MitigatedAnnual report
「株式会社ニューロゲンとは長年にわたり良好な関係を維持しており、現時点でマスターセルバンクの継続的な使用に支障をきたす要因は発生しておりません。」
ニューロゲンとの良好な関係、適切な保管、継続使用に支障をきたす要因がないことを示し、マスターセルバンク使用許諾リスクへの対処状況を説明している。 - FY2020First statedAnnual report
「Because the master cell bank is the cell line that serves as the starting point for manufacturing recombinant human HGF protein, the license is a prerequisite for our principal business activities. If the license agreement were terminated for any reason, it could have a material adverse effect on our pharmaceutical development business.」
Termination of the exclusive license agreement for the master cell bank, the starting point for HGF manufacturing, is identified as a material business risk.